LYN proto-oncogene, Src family tyrosine kinase mRNA (LYN mRNA)

LYN mRNA encodes the LYN proto-oncogene, a member of the Src family of non-receptor tyrosine kinases primarily expressed in hematopoietic cells such as B cells and myeloid cells (UniProt P07948). It serves as a critical mediator of signal transduction, functioning as both a positive and negative regulator of various cell surface receptors, including the B-cell receptor (BCR) and the high-affinity IgE receptor (FcεRI) (NCBI Gene ID: 4067). In the context of disease, LYN mRNA is frequently overexpressed in Chronic Myeloid Leukemia (CML) and Acute Myeloid Leukemia (AML), where it contributes to imatinib resistance and leukemic cell survival (PubMed: 15141221). While clinical treatments currently focus on small-molecule inhibitors like Dasatinib that target the LYN protein, the mRNA itself is an emerging target for RNA-based therapeutics like antisense oligonucleotides (ASOs) and siRNAs designed to silence its expression. These RNA-targeted approaches aim to overcome the limitations of kinase inhibitors by reducing the total pool of LYN protein, thereby inhibiting downstream oncogenic signaling pathways. Additionally, LYN mRNA modulation is being investigated for its potential in treating autoimmune disorders like systemic lupus erythematosus due to its role in regulating immune cell activation thresholds.

Other names

LYNJTK8p53Lynp56LynTyrosine-protein kinase Lyn mRNA

Targeting LYN mRNA via RNA interference (siRNA) or RNase H-mediated degradation (antisense oligonucleotides) to prevent the translation of the LYN kinase protein.